Therapeutic Asset Ratings
1,027 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
rc48-adc
Hepatic Arterial Infusion Chemotherapy
RenJi Hospital
P2
CCC
(53)
rc48-adc
Hormone Receptor Positive / HER2-negative Breast Cancer
SOLTI Breast Cancer Research Group
P2
CCC
(53)
rc48-adc
Kidney Clear Cell Carcinoma
SOLTI Breast Cancer Research Group
P2
CCC
(53)
rc48-adc
Locally Advanced Rectal Cancer (LARC)
brenner baruch
P2
CCC
(53)
rc48-adc
Lung Adenocarcinoma
Jun Liu
P2
CCC
(53)
rc48-adc
Lung Squamous Cell Carcinoma
SOLTI Breast Cancer Research Group
P2
CCC
(53)
rc48-adc
Melanoma
RemeGen Co., Ltd.
P2
CCC
(53)
rc48-adc
Microsatellite Stable
Zhejiang Cancer Hospital
P2
CCC
(53)
rc48-adc
Mismatch Repair-proficient
Zhejiang Cancer Hospital
P2
CCC
(53)
rc48-adc
Other Histology
SOLTI Breast Cancer Research Group
P2
CCC
(53)
rc48-adc
Ovarian Cancer
Second Xiangya Hospital of Central South University
P2
CCC
(53)
rc48-adc
Oxaliplatin
The First Affiliated Hospital of Zhengzhou University
P2
CCC
(53)
rc48-adc
Radiotherapy or Sequential Chemoradiation
Peking University Cancer Hospital & Institute
P2
CCC
(53)
rc48-adc
Richter Transformation
German CLL Study Group
P2
CCC
(53)
rc48-adc
Squamous Esophageal Carcinoma
SOLTI Breast Cancer Research Group
P2
CCC
(53)
rc48-adc
Stomach Adenocarcinoma
SOLTI Breast Cancer Research Group
P2
CCC
(53)
rc48-adc
Gastric Neoplasm
Seagen, a wholly owned subsidiary of Pfizer
P2
CCC
(53)
rc48-adc
Surufatinib
Sun Yat-sen University
P2
CCC
(53)
rc48-adc
Thyroid Carcinoma
SOLTI Breast Cancer Research Group
P2
CCC
(53)
rc48-adc
Triple-Negative Breast Carcinoma
Seagen, a wholly owned subsidiary of Pfizer
P2
CCC
(53)
rc48-adc
Uterine Adenocarcinoma
SOLTI Breast Cancer Research Group
P2
CCC
(53)
rc48-adc
Uterine Carcinosarcoma
SOLTI Breast Cancer Research Group
P2
CCC
(53)
Sacituzumab Tirumotecan
Metastatic Malignant Neoplasm In The Brain
Zhejiang Cancer Hospital
P2
CCC
(53)
Sacituzumab Tirumotecan
EGFR Gene Mutation
Tianjin Medical University Cancer Institute and Hospital
P2
CCC
(53)
Sacituzumab Tirumotecan
EGFR Gene Mutations
Zhejiang Cancer Hospital
P2
CCC
(53)
Showing 426 to 450 of 1,027 assets
Previous
Page 18 of 42
Next